Download PDF
Dtsch Med Wochenschr 2005; 130(44): 2518-2523
DOI: 10.1055/s-2005-918598
Übersichten
Kardiologie / Stoffwechsel
© Georg Thieme Verlag Stuttgart · New York

Lipoprotein(a): Koronare Herzerkrankung - klinische Bedeutung und Therapieoptionen

Lipoprotein(a) in coronary heart disease: clinical significance and therapeutic optionsR. Leischik1 , B. Dworrak1 , H. Gülker1
  • 1Universität Witten-Herdecke
Further Information

Publication History

eingereicht: 17.5.2005

akzeptiert: 18.7.2005

Publication Date:
27 October 2005 (online)

Also available at
    Permissions and Reprints

Seit der Erstbeschreibung von Lipoprotein(a) (Lp(a)) beschäftigt sich die kardiovaskuläre Forschung mit der Frage, wie dieses Molekül sowohl atherogene als auch thrombogene Prozesse beeinflusst. Aufgrund der Vielzahl der Anfragen von Patienten mit Lp(a)-Erhöhung und koronarer Herzerkrankung (KHK) zur Apherese-Therapie oder zu Alternativen ist es notwendig, wissenschaftlich und medizinisch Antworten auf die Frage nach Therapiemöglichkeiten erhöhter Lp(a)-Konzentrationen zu suchen. Seit den 70er Jahren erkannte man zunehmend den pathogenen Einfluss des Lp(a)-Moleküls auf die Entstehung der Arteriosklerose und der KHK. Darüber hinaus wurde in den letzten 15 Jahren auch die negative Bedeutung von Lp(a) für das endotheliale fibrinolytische System beschrieben. Gerade der negative Einfluss auf die Fibrinolyse in Kombination mit der LDL-ähnlichen, arteriosklerotischen Wirkung ist das eigentliche Risiko für atherothrombotische (und spontane) Komplikationen im gesamten kardiovaskulären System und sollte in verstärktem Maße die Forschung beschäftigen. Dabei repräsentiert die Subpopulation der Patienten mit einer kleineren Isoform des apo(a)-Anteils des Lp(a) eine Risikogruppe, die z. B. mittels Immunadsorptionsapherese oder lebenslanger verstärkter Antikoagulation vor weiteren Komplikationen geschützt werden könnte. Die klinische Bedeutung des Lp(a) und die therapeutischen Möglichkeiten werden vor dem Hintergrund der vorliegenden Studien diskutiert.

Literatur

  • 1 Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men.  Clin Cardiol. 2002;  25 287-290
    Google Scholar
  • 2 Akaike M, Azuma H, Kagawa A. et al . Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.  Clin Chem. 2002;  48 1454-1459
    Google Scholar
  • 3 Angelin B. Therapy of lowering lipoprotein(a) levels.  Curr Opin Lipidol. 1997;  8 337-341
    Google Scholar
  • 4 Armstrong V W, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels.  Eur J Clin Invest. 1989;  19 235-240
    Google Scholar
  • 5 Bambauer R, Schiel R, Latza R. Low-density Lipoprotein Apheresis: An Overview.  Therap Apher Dial. 2003;  7 382-390
    Google Scholar
  • 6 Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall.  Eur Heart J. 1990;  11 174-183 (Suppl E)
    Google Scholar
  • 7 Berg K. A new serum type system in man: the LP system.  Acta Pathol Microbio Scand. 1963;  59 369-382
    Google Scholar
  • 8 Boerwinkle E. Genetics of plasma lipoprotein(a) concentrations.  Curr Opin Lipidol. 1992;  3 128-136
    Google Scholar
  • 9 Bosch T, Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction.  Therap Apher Dial. 2003;  7 341-344
    Google Scholar
  • 10 Cantin V, Gagnon F, Moorjani S. et al . Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study.  J Am Coll Cardiol. 1998;  31 519-525
    Google Scholar
  • 11 Carlson L A, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.  J Intern Med. 1989;  226 271-176
    Google Scholar
  • 12 Cremer P, Nagel D, Mann H. et al . Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.  Atherosclerosis. 1997;  129 221-230
    Google Scholar
  • 13 Crouse J R. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.  Coron Artery Dis. 1996;  7 321-326
    Google Scholar
  • 14 Dahlen G H, Guyton J R, Attar M, Farmer J A, Kautz J A, Gotto A M. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography.  Circulation. 1986;  74 758-765
    Google Scholar
  • 15 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.  Circulation. 2000;  102 1082-1085
    Google Scholar
  • 16 Dangas G, Mehran R, Harpel P C. et al . Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation.  J Am Coll Cardiol. 1998;  32 2035-2042
    Google Scholar
  • 17 Dujovne C A, Harris W S, Altman R, Overhiser R W, Black D M. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.  Am J Cardiol. 2000;  85 350-353
    Google Scholar
  • 18 Espeland M A, Marcovina S M, Miller V. et al. for the PEPI investigators . Effect of postmenopausal hormone therapy on lipoprotein(a) concentration.  Circulation. 1998;  97 979-986
    Google Scholar
  • 19 Evans R W, Shpilber O, Shaten B J, Ali S, Kamboh I, Kuller L. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial.  J Clin Epidemiol. 2001;  54 51-57
    Google Scholar
  • 20 Executive summary of the third report of the national cholesterol education programm (NECP) . Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III).  JAMA. 2001;  285 2486-2497
    Google Scholar
  • 21 Frank S, Gauster M, Strauss J, Hrzenjak A, Kostner G M. Adenovirus mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.  Gene Therapy. 2001;  8 425-430
    Google Scholar
  • 22 Ginsberg H N, Kris-Etherton P, Dennis B. et al . Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1.  Arterioscler Thromb Vasc Biol. 1998;  18 441-449
    Google Scholar
  • 23 Gonbert S, Malinsky S, Sposito A C. et al . Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.  Atherosclerosis. 2002;  164 305-311
    Google Scholar
  • 24 Grainger D J, Kirschenlohr H L, Mecalfe J C, Weissberg P L, Wade D P, Lawn R M. Proliferation of human smooth muscle cells promoted by lipoprotein(a).  Science. 1993;  260 1655-1658
    Google Scholar
  • 25 Harpel P C, Chang V T, Borth V. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism.  Proc Natl Acad Sci USA. 1992;  89 10& hairsp;193-10 197
    Google Scholar
  • 26 Hervio L, Chapman J M, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?.  Blood. 1993;  82 392-397
    Google Scholar
  • 27 Jauhiainen M, Koskinen P, Ehnholm. et al . Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.  Atherosclerosis. 1991;  89 59-67
    Google Scholar
  • 28 Jenkins D J, Kendall C W, Marchie A. et al . Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial.  Circulation. 2002;  106 1327-1332
    Google Scholar
  • 29 Kiortsis D N, Tzotas T, Giral P. et al . Changes in lipoprotein(a) levels and hormonal correlation during weight reduction program.  Nutr Metab Cardiovasc Dis. 2001;  11 153-157
    Google Scholar
  • 30 Koschinsky M L, Marcovina S M. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.  Curr Opin Lipidol. 2004;  15 167-174
    Google Scholar
  • 31 Kronenberg F, Kronenberg M F, Kiechl S. et al . Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study (editorial).  Circulation. 1999;  100 1154-1160
    Google Scholar
  • 32 Kronenberg F, Neyer U, Lhotta K. et al . The low molecular weight apo(a)-phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow up.  J Am Soc Nephrol. 1999;  10 1027-1036
    Google Scholar
  • 33 Loscalzo J, Weinhold M, Fless G M, Scanu A M. Lipoprotein(a), fibrin binding and plasminogen activation.  Arteriosclerosis. 1990;  10 240-245
    Google Scholar
  • 34 Luc G, Bard J M, Arveiler D. et al on behalf of the PRIME study group . Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.   Atherosclerosis. 2002;  163 377-384
    Google Scholar
  • 35 Marcovina S M, Koschinsky M L. Lipoprotein(a) concentration and apolipoprotein(a) size - a synergistic role in advanced atherosclerosis?.  Circulation. 1999;  100 1151-1153
    Google Scholar
  • 36 Marcovina S M, Koschinsky M L, Albers J J, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions.  Clin Chem. 2003;  49 1785-1796
    Google Scholar
  • 37 McLean J W, Tomlinson J E, Kuang W J. et al . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.  Nature. 1987;  300 132-137
    Google Scholar
  • 38 Miles L A, Fless G M, Levin E G, Scanu A M, Plow E F. A potential basis for the thrombotic risks associated with lipoprotein(a).  Nature. 1989;  339 301-303
    Google Scholar
  • 39 Miwa K, Nakagawa K, Yoshida N, Taguchi Y, Inoue H. Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm.  J Amer Coll Cardiol. 2000;  35 1200-1205
    Google Scholar
  • 40 Nomura S, Yamamura T, Yamamoto A. et al . The association between lipoprotein(a) and severity of coronary and cerebrovascular atherosclerosis, especially in non-hypercholesterolemic subjects.  Cardiovasc Risk Fact. 1993;  3 336-343
    Google Scholar
  • 41 Nowak-Göttl U, Junker F, Hartmeier M. et al . Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.  Circulation. 1999;  100 743-748
    Google Scholar
  • 42 Phillips B, Ball C, Sackett D. et al .Levels of evidence and grades of recommendation. Oxford: Oxford-Centre for Evidence Based Medicine 2001
    Google Scholar
  • 43 Plenge J K, Hernandez T L, Weil K M. et al . Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction.  Circulation. 2002;  106 1447-1452
    Google Scholar
  • 44 Pokrovsky S N, Sussekov A, Afanasieva O I, Adamova I Y, Lyakishev A A, Kukharchuk V V. Extracorporal immunadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data.  Chem Phys Lipids. 1994;  67/68 323-330
    Google Scholar
  • 45 Scanu A M. Lipoprotein(a) and the atherothrombotic process: Mechanistics insights and clinical implications.  Curr Atheroscler Rep. 2003;  5 106-113
    Google Scholar
  • 46 Schuff-Werner P, Gohlke H, Bartmann U. et al. and the HELP study group . The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease.  Eur J Clin Invest. 1994;  24 724-732
    Google Scholar
  • 47 Seed M, Hoppichler F, Reaveley D. et al . Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.  N Engl J Med. 1990;  322 1494-1499
    Google Scholar
  • 48 Shewmon D A, Stock J L, Rosen C J. et al . Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.  Arterioscler Thromb. 1994;  14 1586-1593
    Google Scholar
  • 49 Sirtori C R, Calabresi L, Ferrara S. et al . L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a).  Nutr Metab Cardiovasc Dis. 2000;  10 247-251
    Google Scholar
  • 50 Terres W, Tatsis E, Pfalzer B, Beil F U, Beilsiegel U, Hamm C W. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a).  Circulation. 1995;  91 948-950
    Google Scholar
  • 51 Thompson G R, Maher V M, Matthews S, Kitano Y, Neuwirth C, Shortt M B. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis.  Lancet. 1995;  345 811-816
    Google Scholar
  • 52 Ullrich H, Lackner K J, Schmitz G. Lipoprotein(a) apheresis in severe coronary heart disease: an immunadsorption method.  Artif Org. 1998;  22 135-139
    Google Scholar
  • 53 Von Depka M, Nowak-Göttl U, Eisert R. et al . Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism.  Blood. 2000;  96 3364-3368
    Google Scholar
  • 54 Von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.  J Am Coll Cardiol. 2001;  37 434-439
    Google Scholar

Dr. med. Roman Leischik

Mittelstraße 13

58095 Hagen

Phone: 02331/182500

Fax: 02331/182570

Email: literatur@dr-leischik.de

      >